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High expression of indoleamine 2,3-dioxygenase gene in prostate
cancer
Abstract
Arginase 2, inducible- and endothelial-nitric-oxide synthase (iNOS and eNOS), indoleamine
2,3-dioxygenase (IDO) and TGF-beta, might impair immune functions in prostate cancer (PCA)
patients. However, their expression was not comparatively analysed in PCA and benign prostatic
hyperplasia (BPH). We evaluated the expression of these genes in PCA and BPH tissues. Seventy-six
patients (42 BPH, 34 PCA) were enrolled. Arginase 2, eNOS and iNOS gene expression was similar in
BPH and PCA tissues. TGF-beta1 gene expression was higher in BPH than in PCA tissues (p=0.035).
IDO gene expression was more frequently detectable (p=0.00007) and quantitatively higher (p=0.00001)
in PCA tissues than in BPH. IDO protein, expressed in endothelial cells from both BPH and PCA, was
detectable in tumour cells in PCA showing evidence of high specific gene expression. In these patients,
IDO gene expression correlated with kynurenine/tryptophan ratio in sera. Thus high expression of IDO
gene is specifically detectable in PCA.
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Abstract  
Arginase 2, inducible and endothelial Nitric-Oxide Synthase (iNOS and eNOS), 
indoleamine 2,3-dioxygenase (IDO) and TGF-β immunosuppressive factors, may 
impair immune functions in prostate cancer (PCA) patients. Their expression, however, 
was not comparatively evaluated in PCA and benign prostatic hyperplasia (BPH). We 
comparatively evaluated the expression of genes encoding immunosuppressive factors 
including IDO in PCA and BPH tissues. 
Seventy-six patients, 42 BPH and 34 PCA, were enrolled. Expression of 
arginase 2, eNOS and iNOS genes was similar in BPH and PCA tissues. TGF-β1 gene 
expression was significantly higher in BPH than in PCA tissues (p=0.035). In contrast 
IDO gene expression was more frequently detectable in PCA as compared to BPH 
(p=0.00007). Its extent was also significantly higher in PCA than in BPH (p=0.00001).  
Immunohistochemistry revealed IDO protein in endothelial cells from both BPH and 
PCA. However, in PCA showing evidence of high specific gene expression, IDO was 
detectable in tumor cells as well. In patients bearing these tumors, IDO gene expression 
correlated with kynurenine/tryptophan ratio in sera.  
These data indicate that while genes encoding Arginase 2, iNOS, eNOS and 
TGF-β immunosuppressive factors are expressed in PCA and BPH, high expression of 
IDO gene is only detectable in PCA.  
 
Key words: benign prostatic hyperplasia; indoleamine 2,3-dioxygenase ; 
immunosuppression; kynurenine; prostate cancer.  
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Introduction 
Prostate cancer (PCA) is the second leading cause of cancer-related death in men 
reaching 31.5% of annual newly diagnosed cancers (Edwards et al, 2005). In order to 
improve the understanding of PCA induction and progression, a contemporary model 
should include a detailed analysis of mechanisms potentially inhibiting immune 
responsiveness to cancer.  
 A number of factors potentially impairing immune responses in PCA patients, 
such as arginase 2 (Bronte et al, 2005), inducible nitric-oxyde synthase (iNOS) (Wang 
et al, 2003), endothelial nitric-oxyde synthase (eNOS) (Tong and Li, 2004) and TGF-β 
(Adler et al, 1999) have been detected in surgical specimens. Interestingly, some of 
these immunosuppressive factors have been suggested to be able to inhibit anti-CD3 or 
PHA induced T cell proliferation (Bronte et al, 2005). However, little is known about 
their comparative expression in PCA and benign prostatic hyperplasia (BPH). Thus, still 
open is the issue of the specificity of the expression of these genes as cancer signature.  
Indoleamine 2,3-dioxygenase (IDO) eventually produced within tumors initiates 
the degradation of Tryptophan along the kynurenine pathway (Stone and Darlington, 
2002) resulting in the production of immunosuppressive catabolites known to suppress 
T cell stimulation in vitro and to cause T cell apoptosis (Terness et al, 2002; Weber et 
al, 2006). IDO expression has thus been proposed as a possible mechanism facilitating 
induction of immune tolerance towards cancer (Uyttenhove et al, 2003). Interestingly, 
metabolites generated by IDO mediated tryptophan digestion have been shown to 
inhibit cytokine induced homeostatic T cell proliferation (Weber et al, 2006). IDO 
expression has indeed been reported in PCA (Uyttenhove et al, 2003). However, no 
comparison with BPH has been provided.  
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In the present study, we comparatively evaluated the expression of genes 
encoding potential immunosuppressive factors including IDO in PCA and BPH tissues. 
Our results indicate that, among genes encoding factors known to affect immune 
response in PCA, IDO gene expression is characterized by the highest specificity for 
PCA tissues. 
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Materials and methods 
Patients and samples  
  
We investigated a consecutive series of 76 specimens from men diagnosed for BPH 
or PCA at the Department of Urology of the University Hospital of Basel (Switzerland) 
in 2007. BPH patients underwent conventional transurethral resection (TUR-P), while 
PCA patients underwent either palliative TUR-P or endoscopic extraperitoneal radical 
prostatectomy (EERP). Relevant clinical data were collected by reviewing patients’ 
files.  
Written informed consent was obtained from patients in accordance with the 
requirements of the Ethical Committee of Basel (EKBB, Ref.Nr. EK: 176/07). 
 
Quantification of gene expression in prostatic tissues by quantitative Real-Time 
PCR 
 
Prostatic tissues resected during surgical procedures were screened for the 
presence of tumours by experienced pathologists at the moment of collection and 
immediately submerged in RNAlater (Ambion, Foster City, CA) and stored at –80°C 
until further processing. Total RNA was extracted by using RNeasy® Mini Kit protocol 
(Qiagen, Basel, Switzerland), treated by Deoxyribonuclease I (DNase I) (Invitrogen, 
Carlsbad, California), and reverse transcribed by using the Moloney Murine Leukemia 
Virus Reverse Transcriptase (M-MLV RT, Invitrogen, Carlsbad, California). 
Quantitative Real-Time PCR was performed by a ABI prism™ 7700 sequence detection 
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system, using the TaqMan® Universal PCR Master Mix, No AmpErase® UNG (both 
from Applied Biosystems, Forster City, CA).  
The following primer sequences were derived from existing literature, as 
indicated below: 
 
GAPDH (Martin et al, 2001) 
Fwd ATGGGGAAGGTGAAGGTCG 
Rev TAAAAGCAGCCCTGGTGACC 
Probe FAM-CGCCCAATACGACCAAATCCGTTGAC-TAMRA 
AMACR A (Mubiru et al, 2004) 
Fwd CGGTTAGCTGGCCACGAT 
Rev GATTCTCACCACTTCTGCCAATT 
Probe FAM- TCAACTATTTGGCTTTGTCAGGTGTTCTCTCAA-TAMRA 
IDO (Uyttenhove et al, 2003) 
Fwd GGTCATGGAGATGTCCGTAA 
Rev ACCAATAGAGAGACCAGGAAGAA 
Probe FAM-CTGTTCCTTACTGCCAACTCTCCAAGAAACTG-TAMRA 
IL-6 (Hartwig et al, 2002) 
Fwd CAGCCCTGAGAAAGGAGACATG 
Rev GGTTCAGGTTGTTTTCTGCCA 
Probe FAM-AGTAACATGTGTGAAAGCAGCAAAGAGGCAC-TAMRA 
TGF-β1 (Mocellin et al, 2001) 
Fwd CGA GAA GCG GTA CCT GAA C 
Rev TGA GGT ATC GCC AGG AAT TGT 
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Probe FAM-CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC-TAMRA 
Arginase 2, iNOS, eNOS, IL-23p19 and IL-17 primers and probes were provided by 
Assays-on-Demand, Gene Expression Products (Applied Biosystems, Forster City, CA). 
Specific gene expression was quantified by using the 2-∆∆CT method (Livak and 
Schmittgen, 2001). Normalization of gene expression was performed using GAPDH as 
reference gene, and samples were considered positive for a ∆CT < 20 cycles. Data were 
expressed as ratio to reference samples represented by lipopolysaccharide (LPS) 
matured dendritic cells (mDC) or phytohemagglutinin (PHA) activated CD4+ T cells, as 
indicated in specific tests.  
 
Immunohistochemistry 
 
Indoleamine 2,3-dioxygenase (IDO) protein was detected on paraffin-embedded 
prostate section by a standard protocol (Bubendorf et al, 1996) using a mouse anti-IDO 
monoclonal antibody (AbD Serotec, Oxford, UK). 
 
Measurement of tryptophan and kynurenine concentrations in serum from BPH 
and PCA patients 
 
 Measurement of tryptophan and kynurenine concentrations in sera from BPH 
and PCA patients was performed as previously described (Chiarugi et al, 2003) by high-
pressure liquid chromatography (HPLC) and fluorimetric detection. Sera were 
deproteinized by mixing it with an equal volume of 10% (w/v) trichloroacetic acid. 
HPLC separation was obtained with a reverse-phase column (Spherisorb S5 ODS2, 25 
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cm) and a mobile phase (1 ml/min flow rate) composed of 5% acetonitrile, 100 mM 
phosphate buffer, pH 3.6, and 1 mM EDTA. Detection was performed with a Perkin-
Elmer (Foster City, CA) model LC 240 fluorimeter (excitation and emission 
wavelengths were 313 and 420 nm, respectively). 
 Kynurenine was measured using HPLC and UV detection. Briefly, HPLC 
separation was obtained with a reverse-phase column (Spherisorb S5 ODS2, 10 cm) and 
a mobile phase (1 ml/min flow rate) composed of 2% acetonitrile, 0.1 mM ammonium 
acetate, and 100 mM acetic acid. Kynurenine was detected at 365 nm with a UV 
detector (Perkin-Elmer model LC 90). 
 
Statistical Analysis 
 
SPSS software (Version 14.0, SPSS Inc., Chicago, IL) was used for statistical 
analyses. Skewness and kurtosis parameters were used to test the “normality” of the 
populations of each group. Mann-Whitney non-parametric test was used to compare 
means for independent samples and Wilcoxon non-parametric test for paired samples 
was used on “non-normal” populations. The frequencies of specific gene expression in 
two groups were assessed by χ2 evaluation. P-values lower than 0.05 were considered to 
be statistically significant. 
  9 
Results 
Clinical profiles of the patients 
 
Average age of the patients enrolled in the study (n=76) was 66.8 +/- 7.7 years 
(range, 49-90). Forty-two of them (55.26%) were diagnosed with benign prostatic 
hyperplasia (BPH) and 34 (44.74%) with prostate cancer (PCA) (table 1). Average age 
was 67.6 +/- 7.4 years (range, 50-81) and 65.8 +/- 8.0 years (range, 49-90) for BPH and 
PCA patients, respectively.  
Of 34 PCA patients, 2 (5.9%) were diagnosed with stage pT1, 1 with stage pT1a, 
1 with stage pT1b, 5 (14.7%) with stage pT2a, 1 with stage pT2b, 20 (59.0%) with stage 
pT2c, 2 (5.9%) with stage pT3a, and 1 with stage pT3b (TNM staging (Wittekind et al, 
2003)) (table 1). One PCA patient had a tumour whose stage at diagnosis could not be 
assessed. 
Average serum Prostate Specific Antigen (PSA) values in the 34 PCA patients 
under investigation was 17.93 +/- 37.62 ng/ml (median: 6.62 ng/ml; range, 1.43-206.00) 
and average Gleason score was 6.55 +/- 1.26 (median: 7.00; range, 3-9). Average serum 
PSA value in BPH patients (n= 34) was 4.82 +/- 5.84 ng/ml (median: 2.30 ng/ml; range, 
0.30-26.00). 
   
Expression of genes encoding immuno-suppressive enzymes from the L-Arginine 
metabolic pathway in PCA and BPH tissues 
 
A number of reports suggest that enzymes involved in L-Arginine metabolism 
may favour cancer growth and development. In particular, arginases were suggested to 
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play a potentially decisive role in PCA induction by enhancing cell proliferation 
(Keskinege et al, 2001). Similarly, inducible NOS (iNOS) has been shown to be 
expressed in prostate cells (Wang et al, 2003) and endothelial NOS (eNOS) is known to 
protect prostate cancer cells from apoptosis (Tong and Li, 2004). Finally, it has been 
suggested that arginase, possibly in synergy with NOSs may be able to inhibit T cell 
response to antigens, thereby favouring tumour escape from recognition by the immune 
system (Rodriguez et al, 2004).  
 We quantitatively analyzed arginase 2, iNOS and eNOS gene expression in our 
series of PCA and BPH tissues. As shown in figure 1, arginase 2 gene expression was 
detectable in 22/33 (66.7%) and in 18/24 (75.0%) BPH and PCA specimens, 
respectively (χ2 = 0.50). Furthermore, under a quantitative point of view, in positive 
cases, arginase 2 gene expression did not significantly differ in PCA or BPH (p=0.232).  
iNOS gene was found to be significantly (χ2 = 0.04) more frequently expressed 
in PCA specimens (26/32, 81.3%) as compared to BPH (23/39, 59.0%). However, no 
significant differences in the extent of specific gene expression in positive cases were 
observed (p=0.111). On the other hand, eNOS was similarly expressed in 28/39 (71.8%) 
and in 26/32 (81.3%) of BPH and PCA specimens, respectively (χ2 = 0.35). 
Furthermore, no significant quantitative differences in eNOS gene expression between 
BPH and PCA positive cases were detectable (p=0.515).  
 
Expression of genes encoding cytokines in PCA and BPH tissues 
 
 A number of cytokines have been suggested to be involved in PCA 
pathogenesis. In particular, IL-6 is known to be a mediator of PCA morbidity and 
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disease activity, and may act as a cell growth factor and protect cancer cells from death. 
In addition, it has been demonstrated that patients with metastatic PCA have increased 
IL-6 serum levels (Twillie et al, 1995). We comparatively evaluated IL-6 gene 
expression in BPH and PCA tissues.  
 As shown in figure 2, IL-6 was expressed in 18/39 (46.2%) and in 26/32 (81.3%) 
of BPH and PCA specimens, respectively (χ2 = 0.002). The extent of gene expression in 
positive cases was significantly higher in PCA as compared to BPH (p=0.00018), 
indicating that IL-6 gene expression might indeed be of use in discriminating PCA from 
BPH tissues. 
 All three TGF-β isoforms, TGF-β1, -2 and -3 have been detected in prostate cells 
(reviewed in (Steiner, 1995)). They share similar biological properties but present 
slightly different tissue distribution (Massague, 1990). While TGF-β2 mRNA appears to 
be increased in BPH (Mori et al, 1990), TGF-β1 mRNA levels have been suggested to 
be increased in PCA (Merz et al, 1994). Additionally, patients with metastatic PCA 
displaying high levels of serum IL-6 have also been reported to present increased serum 
levels of TGF-β1 (Adler et al, 1999). On the other hand, in normal prostate, TGF-β 
inhibits epithelial cell proliferation and stimulates apoptosis, thus acting in a tumour 
suppressor-like manner (Bello-DeOcampo and Tindall, 2003).  
In our series of samples, TGF-β1 gene was expressed in 32/39 (82.1%) and in 
30/32 (93.8%) of BPH and PCA specimens, respectively (χ2 = 0.14). However, 
unexpectedly, TGF-β1 gene expression in positive cases was quantitatively significantly 
lower in PCA as compared to BPH tissues (p=0.035).  
 The expansion of a newly characterized subset of CD4+ helper T cells 
specifically secreting IL-17 (Aggarwal and Gurney, 2002) is promoted by IL-23 which 
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shares its p40 chain with IL-12 (Veldhoen et al, 2006). The role played by these 
cytokines in tumour growth and immune responsiveness against tumours is debated. IL-
23 has been reported to promote tumour incidence and growth (Langowski et al, 2006), 
but also to induce immune enhancement and anti-tumour activity (Hao and Shan, 2006). 
No data are available so far regarding IL-23 expression and PCA. Also regarding IL-17, 
conflicting data have been reported on its capacity to promote or inhibit tumour growth 
“in vivo” (Aggarwal and Gurney, 2002; Numasaki et al, 2003). Interestingly, IL-17 gene 
expression has been detected in prostate tissues (Steiner et al, 2003).  
  IL-23A gene was only marginally expressed, in 7/32 (21.9%) and 6/25 (24%) of 
the BPH and PCA specimens, respectively (χ2 = 0.85), under investigation (Figure 2). 
No significant quantitative differences were detectable between positive samples of the 
two groups (p=0.784).  
Regarding IL-17 (figure 2), only 6/39 (15.4%) and 8/32 (25%) of BPH and PCA 
specimens, respectively (χ2 = 0.31) were positive for specific gene expression, and no 
significant quantitative differences could be observed between positive PCA and BPH 
(p=0.343).  
 
IDO expression in prostatic tissues 
 
 Tryptophan degradation by IDO has been proposed as a mechanism favouring 
tumour escape from immune response  (Uyttenhove et al, 2003).  
We investigated IDO gene expression in our series of specimens. As shown in 
figure 3 (panel 1), IDO gene expression was detectable in 12/42 (28.6%) and in 24/32 
(75%) of BPH and PCA samples, respectively (χ2 = 0.000075). In addition, under a 
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quantitative point of view, IDO gene expression in positive cases was significantly 
higher in PCA as compared to BPH (p=0.00001). 
 Interestingly, the existence of two subpopulations of PCA showing evidence of 
different IDO gene expression clearly emerged. Indeed, 9/24 (37.5%) PCA were high 
and 15/24 (62.5%) were low IDO expressers, with a difference in gene expression of 
≥100 times. Furthermore, IDO gene expression in PCA and BPH tissues was 
significantly (p=0.004, data not shown) correlated with the expression of the gene 
encoding Alpha-methyl CoenzymeA racemases A (AMACR A), known to be over-
expressed in prostatic adenocarcinoma as compared to normal tissue (Rubin et al, 
2002). 
Prompted by these data we investigated IDO expression at the protein level by 
immunohistochemical analysis on paraffin embedded PCA and BPH tissues. 
Surprisingly, as illustrated in figure 3 (panel 2: c and d), IDO protein was almost 
exclusively detectable in endothelial cells in BPH and PCA tissues displaying low 
levels of IDO gene expression. However in PCA displaying high levels of IDO gene 
expression, focal IDO specific staining in 2-5% of tumor cells was clearly detectable 
(Figure 3 panel 2: e. and f.). 
To determine if local IDO expression in PCA could have a systemic impact, we 
measured the concentrations of tryptophan and of its IDO dependent metabolite 
kynurenine in sera from BPH (n=33) and PCA (n=34) patients, as described in materials 
and methods. Overall, no significant differences (p=0.111) were detected in 
kynurenine/tryptophan ratios in sera from PCA as compared to BPH patients (data not 
shown). However, in the subgroup of PCA specimens displaying a high level of IDO 
gene expression, a significant correlation between the expression of this gene and  
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serum kynurenine/tryptophan ratios in sera (P=0.0045, R2=0.8406) were observed, thus 
suggesting an increased metabolism of the target aminoacid (figure 3 panel 3). 
In these patients, a highly significant correlation between IDO and TGF-β1 gene 
expression was also detectable (table 2). In contrast IDO gene expression in PCA 
tissues did not correlate with Gleason score, pT stage or PSA levels. 
  15 
Discussion 
 
Neoplastic cells are detectable with high frequency in prostates from aged males. 
However, only in a minority of cases outgrowth of clinically relevant cancers can be 
observed. Mechanisms governing this transition are unclear, but it is tempting to 
speculate that defective tumour specific immune responsiveness could be involved.  
Indeed, a number of factors have been suggested to be able to impair the 
functions of the immune system in PCA. However, the expression of genes encoding 
these factors in PCA and in BPH has not been comparatively addressed so far.  
In this study, we show that PCA and BPH specimens display a similar 
expression of several genes encoding potentially immunosuppressive factors, such 
Arginase 2, iNOS and eNOS. Conflicting data have been reported regarding the 
capacity of IL-23 and IL-17 to favour or inhibit cancer growth (Benchetrit et al, 2002; 
Langowski et al, 2006; Numasaki et al, 2003). We found that the overall expression of 
the genes encoding these factors is weak in prostate specimens, but nevertheless similar 
in BPH and PCA (Steiner et al, 2003). Interestingly, a significant decrease in TGF-β1 
gene expression in PCA as compared to BPH was concomitantly detected.  
Although the specimens under investigation were carefully screened for the 
presence of tumours by experienced pathologists at the moment of tissue collection, we 
cannot formally exclude that they did not actually contain tumour cells. Remarkably, 
however, the expression of the gene encoding IL-6, previously indicated as a possible 
mediator of prostate cancer morbidity (Twillie et al, 1995), was found to be highly 
significantly enhanced in PCA as compared to BPH tissues under investigation. These 
data help validating the integrity of our technical approach.  
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Indoleamine 2,3-dioxygenase (IDO), has been proposed to induce tumoral 
immune resistance (Uyttenhove et al, 2003). While expression of IDO gene has been 
detected in PCA (Uyttenhove et al, 2003) its cancer specificity has not been investigated 
so far. 
We found that although IDO gene expression is also detectable in BPH 
specimens, it is strongly enhanced in a sizeable percentage of PCA specimens. Notably, 
overall IDO gene expression is significantly correlated with the expression of the gene 
encoding  AMACR A, a candidate biomarker for PCA (Xu et al, 2000). Most 
interestingly, in the subgroup of PCA patients whose tumours express high levels of 
IDO gene, a significant increase of the kynurenine/tryptophan ratio is detectable in the 
sera. These data suggest that the impact of IDO gene expression could extend beyond 
tumour microenvironment and result in systemic effects.  
Interestingly, in our study, IDO protein was frequently expressed by endothelial 
cells rather than by tumour cells in BPH and PCA tissues expressing low level of IDO 
gene. Notably, IDO has been shown to be expressed at the protein level mainly by 
vascular endothelial cells in term placenta (Ligam et al, 2005) and in renal cell 
carcinoma (Riesenberg et al, 2007). Furthermore, inhibition of IDO activity is known to 
improve the ability of HUVEC cells to stimulate allogenic T cell responses, and 
HUVEC cells transfected with the IDO gene induce anergy in allospecific T cells 
(Beutelspacher et al, 2006).  
However, in PCA specimens of our series where high levels of IDO gene 
expression were observed, IDO protein was also focally detectable in tumour cells. 
Remarkably, prostate cancer cells expressing IDO protein were often located in areas of 
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inflammation and atrophic glands and ducts were found to be positive for IDO specific 
staining in PCA.  
Taken together, our findings indicate that while Arginase 2, eNOS and iNOS are 
similarly expressed in both BPH and PCA, high IDO gene expression is typically 
detectable only in a subgroup of PCA, but not in BPH. In patients bearing these tumors 
a high kynurenine/tryptophan ratio can also be observed in sera. Further studies with 
adequate follow up timing are warranted to address the potential diagnostic and/or 
prognostic significance of high IDO gene expression in PCA.  
Notably, IDO might eventually represent an attractive target for the development 
of new drugs of potential use in the treatment of PCA. Indeed, IDO inhibition is not 
intrinsically cytotoxic, and potent bioactive IDO inhibitors such as 1-methyl-DL-
tryptophan (1-MT) and methyl-thiohydantoin-tryptophan (MTH-trp) have been shown 
to cooperate with diverse chemotherapeutic agents to effectively promote regression of 
established tumours in experimental models (Muller et al, 2005). 
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Figures legends 
 
Figure 1. Expression of genes encoding immuno-suppressive enzymes from the L-
Arginine metabolic pathway in PCA and BPH tissues. Total RNA was extracted 
from BPH and PCA tissues, DNAse treated, reverse transcribed and analyzed by 
quantitative Real-Time PCR for Arginase 2 (BPH: n=33, PCA: n=24), iNOS and eNOS 
(BPH: n=39, PCA: n=32) specific gene expression. Data are expressed as ratio to a 
positive control reference sample (cDNA from LPS matured dendritic cells - mDC). 
 
Figure 2. Expression of genes encoding cytokines in PCA and BPH tissues. Total 
RNA was extracted from BPH and PCA tissues, DNAse treated, reverse transcribed and 
analyzed by quantitative Real-Time PCR for IL-6, TGF-β1, IL-17 (BPH: n=39, PCA: 
n=32) and IL-23p19 (BPH: n=32, PCA: n=25) gene expression. Data are expressed as 
ratio to a positive control reference sample represented by LPS matured dendritic cells 
(mDC) and PHA activated CD4+ T cells for IL-6 or TGF-β1and IL-23p19 or IL-17, 
respectively.  
 
Figure 3. IDO expression in prostatic tissues.  
(Panel 1) IDO gene expression in prostatic tissues. Total RNA was extracted from 
BPH (n=42) and PCA (n=32) tissues, DNAse treated, reverse transcribed and analyzed 
by quantitative real-Time PCR for IDO gene expression. Data were expressed as ratio to 
a reference positive control represented by LPS matured dendritic cells (mDC).  
(Panel 2) Immuno-histochemical detection of IDO in PCA and BPH tissues. (a.) 
Decidua was used as positive control tissue and stained with IDO specific antibodies 
(400X). (b.) PCA tissue negative for IDO gene expression (400X). (c.) BPH tissue 
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showing weak IDO gene expression, and (d.) PCA tissue showing weak IDO gene 
expression and displaying IDO+ endothelial cells in capillaries and IDO- tumor cells 
(630X). (e,f) PCA tissues expressing high levels of IDO gene expression and showing 
IDO+ tumour cells, especially in inflamed regions (panel f) (400X). Arrows indicate 
IDO+ cells.  
(Panel 3) Systemic impact of IDOhigh gene expression in PCA tissues.  A subgroup of 
PCA (n=9) tissues highly positive for IDO gene expression (see panel 1) was identified. 
IDO gene expression in these tumours was correlated to kynurenine /tryptophan ratio in 
sera from the corresponding patients sampled simultaneously to collection of surgical 
specimens. 
NA: Not Available
Patient Age (y) Operation technique
PSA 
(ng/ml) Patient Age (y)
Operation 
technique
PSA 
(ng/ml)
Gleason 
score
pT 
stage
1 72 TUR-P NA PCA IDOlow 1 60 EERP 6.43 6 2c
2 75 TUR-P NA n=25 2 61 EERP 8.50 6 2a
3 72 TUR-P NA 3 59 EERP 7.20 7 2c
4 78 TUR-P NA 4 69 EERP 48.00 7 3a
5 78 TUR-P 18.60 5 74 EERP 1.43 7 2c
6 75 TUR-P 2.07 6 83 TUR-P 106.00 9 1b
7 78 TUR-P NA 7 71 EERP 10.00 5 2a
8 62 TUR-P 1.26 8 56 EERP 4.40 7 2c
9 69 TUR-P 3.93 9 64 EERP 6.50 6 2c
10 67 TUR-P 4.40 10 64 EERP 10.00 6 2c
11 67 TUR-P 17.00 11 49 EERP 35.00 7 3b
12 69 TUR-P 1.16 12 90 TUR-P 206.00 3 NA
13 65 TUR-P 6.40 13 67 EERP 4.40 7 2c
14 65 TUR-P 1.36 14 74 EERP 17.00 7 3a
15 73 TUR-P 10.10 15 62 EERP 6.64 6 2c
16 52 TUR-P 1.66 16 66 EERP 6.20 6 2a
17 50 TUR-P 1.11 17 67 EERP 13.30 7 2c
18 61 TUR-P 1.67 18 60 EERP 5.70 9 2b
19 68 TUR-P 5.40 19 66 EERP 6.04 6 2c
20 60 TUR-P 2.12 20 54 EERP 10.00 7 2c
21 62 TUR-P 2.30 21 68 EERP 6.88 7 2c
22 63 TUR-P NA 22 68 EERP 3.44 7 2c
23 59 TUR-P 4.25 23 76 EERP 11.52 6 2c
24 65 TUR-P 1.24 24 65 TUR-P 6.19 6 1a
25 58 TUR-P 2.66 25 69 EERP 4.10 7 2c
26 65 TUR-P 2.96
27 65 TUR-P 26.00 PCA IDOhigh 26 73 TUR-P 6.50 3 1
28 72 TUR-P 1.79 n=9 27 72 TUR-P 9.70 NA 1
29 61 TUR-P 2.30 28 61 EERP 4.78 6 2a
30 69 TUR-P 8.14 29 66 EERP 4.50 7 2c
31 61 TUR-P 3.50 30 57 EERP 8.80 7 2c
32 67 TUR-P 15.70 31 58 EERP 10.90 7 2c
33 73 TUR-P 1.74 32 66 EERP 4.60 6 2a
34 65 TUR-P 1.31 33 59 EERP 6.60 7 2c
35 64 TUR-P 0.90 34 63 EERP 2.44 9 2c
36 62 TUR-P 2.93
37 69 TUR-P 0.30
38 78 TUR-P 2.40
39 81 TUR-P NA
40 63 TUR-P 1.26
41 81 TUR-P NA
42 81 TUR-P 4.00
Mean 67.6 4.82 Mean 65.8 17.93 6.55
Standard 
deviation 7.4 5.84
Standard 
deviation 8.0 37.62 1.26
Table 1. Clinical profiles of the patients
PCA Patients n=34BPH Patients n=42
Figure 1. Expression of genes encoding immuno-suppressive enzymes from the L-Arginine metabolic 
pathway in PCA and BPH tissues
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1. IDO gene expression in prostatic tissues
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3. Systemic impact in IDOhigh gene expression PCA tissues 
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P = 0.0045
p R2 p R2 p R2
PSA 0.5459 -0.1108 0.5545 -0.2284 0.7408 -0.0730
Gleason score 0.1197 0.2854 0.1310 0.5810 0.7464 0.0713
pT stage 0.2044 -0.2305 0.5477 -0.2322 0.9834 -0.0046
Kyn/Trp a 0.3889 0.1577 0.0045 0.8406 0.7254 -0.0774
IL-6 b 0.3263 -0.1792 0.3238 -0.3723 0.9906 -0.0026
TGF-β1 b 0.1284 0.2745 0.0028 0.8627 0.6256 -0.1074
PCA patients IDOlow/neg 
expressers                   
n=25
Table 2. Correlation between IDO gene expression in PCA tissues and clinical profiles
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